Answers are grounded in this paper and cite their sources.
FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐Sevilla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: